Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 23, 2014, Pages 8331-8338

  Ankomah, Peter ^a   Levin, Bruce R ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Immunology; Population dynamics

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; COLONY FORMING UNIT; COMPUTER SIMULATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG MEGADOSE; HOST RESISTANCE; IMMUNE RESPONSE; INFECTION; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PHARMACODYNAMICS; POPULATION DYNAMICS; PRIORITY JOURNAL;

IMMUNOLOGY; POPULATION DYNAMICS;

ADAPTIVE IMMUNITY; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MICROBIAL; HUMANS; MODELS, THEORETICAL; TREATMENT OUTCOME;

EID: 84902167811     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1400352111     Document Type: Article

References (99)

1. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 26(1):1-10, quiz 11-12.
2. Drusano GL (2007) Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis 45(Suppl 1):S89-S95.
3. Mattie H (1981) Kinetics of antimicrobial action. Rev Infect Dis 3(1):19-27.
4. Garrett ER, Miller GH, Brown MR (1966) Kinetics and mechanisms of action of antibiotics on microorganisms. V. Chloramphenicol and tetracycline affected Escherichia coli generation rates. J Pharm Sci 55(6):593-600.
5. Garrett ER, Won CM (1973) Kinetics and mechanisms of drug action on microorganisms. XVII. Bactericidal effects of penicillin, kanamycin, and rifampin with and without organism pretreatment with bacteriostatic chloramphenicol, tetracycline, and novobiocin. J PharmSci 62(10):1666-1673.
6. Mueller M, de la Peña A, Derendorf H (2004) Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: Kill curves versus MIC. Antimicrob Agents Chemother 48(2):369-377. (Pubitemid 38141689)
7. Mouton JW, et al. (2011) Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat 14(2):107-117.
8. Clinical and Laboratory Standards Institute (2013) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard (Clinical and Laboratory Standards Institute, Wayne, PA), 9th Ed.
9. Clinical and Laboratory Standards Institute (2005) Performance Standards for Antimicrobial Susceptibility Testing. Fifteenth Informational Supplement (Clinical and Laboratory Standards Institute, Wayne, PA).
10. European Committee on Antimicrobial Susceptibility Testing (2013) The European Committee on Antimicrobial Susceptibility Testing: Clinical Breakpoints (European Committee on Antimicrobial Susceptibility Testing, Basel).
11. Preston SL, et al. (1998) Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials. JAMA 279(2):125-129. (Pubitemid 28068302)
12. Forrest A, et al. (1993) Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37(5):1073-1081. (Pubitemid 23141323)
13. Ambrose PG, et al. (2001) Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 45(10):2793-2797. (Pubitemid 32906673)
14. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS, Jr. (1999) Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 43(3):623-629. (Pubitemid 29109529)
15. McKinnon PS, Davis SL (2004) Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. Eur J Clin Microbiol Infect Dis 23(4):271-288. (Pubitemid 38669938)
16. Udekwu KI, Parrish N, Ankomah P, Baquero F, Levin BR (2009) Functional relationship between bacterial cell density and the efficacy of antibiotics. J Antimicrob Chemother 63(4):745-757.
17. Tapsall JW, et al. (1998) Failure of azithromycin therapy in gonorrhea and discorrelation with laboratory test parameters. Sex Transm Dis 25(10):505-508. (Pubitemid 28553604)
18. Webb GF, D'Agata EM, Magal P, Ruan S (2005) A model of antibiotic-resistant bacterial epidemics in hospitals. Proc Natl Acad Sci USA 102(37):13343-13348. (Pubitemid 41325025)
19. Bonhoeffer S, Lipsitch M, Levin BR (1997) Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci USA 94(22):12106-12111. (Pubitemid 27467850)
20. Bergstrom CT, Lo M, Lipsitch M (2004) Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci USA 101(36):13285-13290. (Pubitemid 39209657)
21. D'Agata EM, Magal P, Olivier D, Ruan S, Webb GF (2007) Modeling antibiotic resistance in hospitals: The impact of minimizing treatment duration. J Theor Biol 249(3):487-499. (Pubitemid 350046634)
22. D'Agata EM, Dupont-Rouzeyrol M, Magal P, Olivier D, Ruan S (2008) The impact of different antibiotic regimens on the emergence of antimicrobial- resistant bacteria. PLoS One 3(12):e4036.
23. Lipsitch M, Levin BR (1997) The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 41(2):363-373. (Pubitemid 27111032)
24. Lipsitch M, Levin BR (1998) Population dynamics of tuberculosis treatment: Mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int J Tuberc Lung Dis 2(3):187-199. (Pubitemid 28123517)
25. Ankomah P, Levin BR (2012) Two-drug antimicrobial chemotherapy: A mathematical model and experiments with Mycobacterium marinum. PLoS Pathog 8(1):e1002487.
26. Ankomah P, Johnson PJ, Levin BR (2013) The pharmaco -, population and evolutionary dynamics of multi-drug therapy: Experiments with S. aureus and E. coli and computer simulations. PLoS Pathog 9(4):e1003300.
27. Imran M, Smith H (2007) The dynamics of bacterial infection, innate immune response, and antibiotic treatment. Discrete Cont Dynamical Systems 8(Ser B):127-143.
28. Handel A, Margolis E, Levin BR (2009) Exploring the role of the immune response in preventing antibiotic resistance. J Theor Biol 256(4):655-662.
29. Geli P, Laxminarayan R, Dunne M, Smith DL (2012) "One-size-fits- all"? Optimizing treatment duration for bacterial infections. PLoS One 7(1):e29838.
30. Arason VA, Sigurdsson JA (2010) The problems of antibiotic overuse. Scand J Prim Health Care 28(2):65-66.
31. Levin BR, Udekwu KI (2010) Population dynamics of antibiotic treatment: A mathematical model and hypotheses for time-kill and continuous-culture experiments. Antimicrob Agents Chemother 54(8):3414-3426.
32. Monod J (1949) The growth of bacterial cultures. Annu Rev Microbiol 3:371-394.
33. Kahlmeter G, et al. (2003) European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 52(2):145-148. (Pubitemid 36986868)
34. Sissons JGP, Borysiewicz LK, Cohen J (1994) Immunology of Infection (Kluwer Academic Publishers, Dordrecht, The Netherlands).
35. Davies D (2003) Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov 2(2):114-122.
36. Regoes RR, et al. (2004) Pharmacodynamic functions: A multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother 48(10):3670-3676. (Pubitemid 39304588)
37. Stewart FM, Levin BR (1973) Partitioning of resources and outcome of interspecific competition-model and some general considerations. Am Nat 107(954):171-198.
38. Kochin BF, Yates AJ, de Roode JC, Antia R (2010) On the control of acute rodent malaria infections by innate immunity. PLoS One 5(5):e10444.
39. Antia R, Levin BR, May RM (1994) Within-host population-dynamics and the evolution and maintenance of microparasite virulence. Am Nat 144(3):457-472. (Pubitemid 2139150)
40. Handel A, Longini IM, Jr., Antia R (2007) Neuraminidase inhibitor resistance in influenza: Assessing the danger of its generation and spread. PLoS Comput Biol 3(12):e240.
41. zur Wiesch PA, Kouyos R, Engelstädter J, Regoes RR, Bonhoeffer S (2011) Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect Dis 11(3):236-247.
42. Johnson PJ, Levin BR (2013) Pharmacodynamics, population dynamics, and the evolution of persistence in Staphylococcus aureus. PLoS Genet 9(1):e1003123.
43. Wiuff C, et al. (2005) Phenotypic tolerance: Antibiotic enrichment of noninherited resistance in bacterial populations. Antimicrob Agents Chemother 49(4):1483-1494. (Pubitemid 40463380)
44. Gwaltney JM, Jr., Wiesinger BA, Patrie JT (2004) Acute community-acquired bacterial sinusitis: The value of antimicrobial treatment and the natural history. Clin Infect Dis 38(2):227-233. (Pubitemid 38113031)
45. Ternhag A, Asikainen T, Giesecke J, Ekdahl K (2007) A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused by infection with Campylobacter species. Clin Infect Dis 44(5):696-700.
46. Levin BR, Stewart FM, Chao L (1977) Resource-limited growth, competition, and predation: A model and experimental studies with bacteria and bacteriophage. Am Nat 111(977):3-24.
47. Gumbo T, et al. (2004) Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 190(9):1642-1651. (Pubitemid 39411014)
48. Tam VH, et al. (2005) Bacterial-population responses to drug-selective pressure: Examination of garenoxacin's effect on Pseudomonas aeruginosa. J Infect Dis 192(3):420-428. (Pubitemid 41023120)
49. Tam VH, et al. (2005) Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 49(12):4920-4927. (Pubitemid 41778901)
50. Knudsen JD, Fuursted K, Raber S, Espersen F, Frimodt-Moller N (2000) Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob Agents Chemother 44(5):1247-1254. (Pubitemid 30228302)
51. Daikos GL, Jackson GG, Lolans VT, Livermore DM (1990) Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis 162(2):414-420. (Pubitemid 20239957)
52. Knudsen JD, et al. (2003) Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models. Antimicrob Agents Chemother 47(8):2499-2506. (Pubitemid 36919451)
53. Moore RD, Lietman PS, Smith CR (1987) Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155(1):93-99. (Pubitemid 17225088)
54. Dunbar LM, et al. (2003) High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm. Clin Infect Dis 37(6):752-760. (Pubitemid 37153652)
55. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ (2004) Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 43(13):925-942. (Pubitemid 39447034)
56. Blaser J, Stone BB, Groner MC, Zinner SH (1987) Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 31(7):1054-1060. (Pubitemid 17099578)
57. Thorburn CE, Edwards DI (2001) The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance. J Antimicrob Chemother 48(1):15-22. (Pubitemid 32684720)
58. Firsov AA, et al. (2003) In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 47(5):1604-1613. (Pubitemid 36548544)
59. Tam VH, Louie A, Deziel MR, Liu W, Drusano GL (2007) The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: A new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother 51(2):744-747. (Pubitemid 46185299)
60. Fantin B, Farinotti R, Thabaut A, Carbon C (1994) Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa. J Antimicrob Chemother 33(3):563-569. (Pubitemid 24110872)
61. Stearne LE, Goessens WH, Mouton JW, Gyssens IC (2007) Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection. Antimicrob Agents Chemother 51(10):3605-3611. (Pubitemid 47519350)
62. Thomas JK, et al. (1998) Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 42(3):521-527. (Pubitemid 28114802)
63. Hansen CR, Pressler T, Hoiby N, Johansen HK (2009) Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients. J Cyst Fibros 8(1):58-62.
64. Guillemot D, et al. (1998) Low dosage and long treatment duration of beta-lactam: Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 279(5):365-370. (Pubitemid 28133865)
65. Marcusson LL, Frimodt-Møller N, Hughes D (2009) Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog 5(8):e1000541.
66. Olofsson SK, Marcusson LL, Komp Lindgren P, Hughes D, Cars O (2006) Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: Relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother 57(6):1116-1121. (Pubitemid 44644413)
67. Olofsson SK, Geli P, Andersson DI, Cars O (2005) Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli. Antimicrob Agents Chemother 49(12):5081-5091. (Pubitemid 41778924)
68. Wiuff C, Lykkesfeldt J, Svendsen O, Aarestrup FM (2003) The effects of oral and intramuscular administration and dose escalation of enrofloxacin on the selection of quinolone resistance among Salmonella and coliforms in pigs. Res Vet Sci 75(3):185-193. (Pubitemid 37192997)
69. Odenholt I, Gustafsson I, Löwdin E, Cars O (2003) Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: In vitro kinetic model. Antimicrob Agents Chemother 47(2):518-523. (Pubitemid 36158075)
70. Klugman KP, Friedland IR, Bradley JS (1995) Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob Agents Chemother 39(9):1988-1992.
71. Viladrich PF, et al. (1996) High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins. Antimicrob Agents Chemother 40(1):218-220. (Pubitemid 26019700)
72. Diacon AH, et al. (2007) Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 51(8):2994-2996. (Pubitemid 47206244)
73. van Ingen J, et al. (2011) Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis 52(9):e194-e199.
74. Roberts JA, Kruger P, Paterson DL, Lipman J (2008) Antibiotic resistance-what's dosing got to do with it? Crit Care Med 36(8):2433-2440.
75. Corvaisier S, et al. (1998) Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model. Antimicrob Agents Chemother 42(7):1731-1737. (Pubitemid 28311571)
76. Delacher S, et al. (2000) A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans. J Antimicrob Chemother 46(5):733-739.
77. Hyatt JM, Nix DE, Stratton CW, Schentag JJ (1995) In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa. Antimicrob Agents Chemother 39(8):1711-1716.
78. Madaras-Kelly KJ, Ostergaard BE, Hovde LB, Rotschafer JC (1996) Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother 40(3):627-632.
79. Bonapace CR, Friedrich LV, Bosso JA, White RL (2002) Determination of antibiotic effect in an in vitro pharmacodynamic model: Comparison with an established animal model of infection. Antimicrob Agents Chemother 46(11):3574-3579. (Pubitemid 35192928)
80. Boylan CJ, et al. (2003) Pharmacodynamics of oritavancin (LY333328) in a neutropenicmouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 47(5):1700-1706. (Pubitemid 36548557)
81. Kim MK, et al. (2002) Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. Antimicrob Agents Chemother 46(10):3185-3192.
82. Louie A, et al. (2001) Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 45(3):845-851. (Pubitemid 32182035)
83. Wallis RS, et al. (2011) Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother 55(2):567-574.
84. Diacon AH, et al. (2010) Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 54(8):3402-3407.
85. Supajatura V, et al. (2002) Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest 109(10):1351-1359. (Pubitemid 34546900)
86. Cowdery JS, Chace JH, Yi AK, Krieg AM (1996) Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol 156(12):4570-4575. (Pubitemid 26174435)
87. + T cell differentiation: Initial antigen encounter triggers a developmental program in naïve cells. Nat Immunol 2(5):415-422.
88. Mercado R, et al. (2000) Early programming of T cell populations responding to bacterial infection. J Immunol 165(12):6833-6839. (Pubitemid 32001151)
89. Bajénoff M, Wurtz O, Guerder S (2002) Repeated antigen exposure is necessary for the differentiation, but not the initial proliferation, of naive CD4+ T cells. J Immunol 168(4):1723-1729. (Pubitemid 34135770)
90. Oleson FB, Jr, et al. (2000) Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 44(11):2948-2953.
91. Read AF, Day T, Huijben S (2011) The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proc Natl Acad Sci USA 108(Suppl 2):10871-10877.
92. Huijben S, et al. (2010) Chemotherapy, within-host ecology and the fitness of drugresistant malaria parasites. Evolution 64(10):2952-2968.
93. Crow JF, Kimura M (1970) An Introduction to Population Genetics Theory (Harper & Row, New York).
94. Comas I, et al. (2012) Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 44(1):106-110.
95. Björkman J, Hughes D, Andersson DI (1998) Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci USA 95(7):3949-3953. (Pubitemid 28173234)
96. Levin BR, Perrot V, Walker N (2000) Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 154(3):985-997. (Pubitemid 30140690)
97. Schrag SJ, Perrot V (1996) Reducing antibiotic resistance. Nature 381(6578):120-121.
98. Nagaev I, Björkman J, Andersson DI, Hughes D (2001) Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol Microbiol 40(2):433-439. (Pubitemid 32391637)
99. Ehrlich P (1913) Address in Pathology, ON CHEMIOTHERAPY: Delivered before the Seventeenth International Congress of Medicine. BMJ 2(2746):353-359.